MBX Biosciences Q3 net loss $18.1M; cash $277M funds into mid-2027; IPO raised $251M

MBX Biosciences, Inc.

2024-Q3 EPS reported -$15.42

Net loss for Q3 2024 was $18.1M vs $10.2M in Q3 2023; R&D spend rose to $16.7M from $9.1M.
Cash, equivalents and marketable securities $277.1M as of Sep 30, 2024 (up from $80.7M at Dec 31, 2023).
IPO and Series C gross proceeds totaled approximately $251.2M.
Phase 1 trial of MBX 1416 (post-bariatric hypoglycemia) last subject visit by late Nov 2024; topline results early Jan 2025.
Phase 2 Avail trial of MBX 2109 (hypoparathyroidism) enrollment completion expected Q1 2025; topline results Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.